Form 4: ARTIVION CCO Sells 5,000 Shares Under 10b5-1 Plan

ARTIVION's Chief Commercial Officer, John E. Davis, reported the sale of 5,000 shares of common stock at $45.11 per share on December 15, 2025, executed under a pre-arranged Rule 10b5-1 plan.

Summary

• John E. Davis, Chief Commercial Officer of ARTIVION, INC. (AORT), reported a transaction involving the company's common stock.
• On December 15, 2025, Mr. Davis disposed of 5,000 shares of ARTIVION common stock.
• The shares were sold at a price of $45.11 per share.
• This transaction was made pursuant to a contract, instruction, or written plan for the sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Mr. Davis beneficially owns 193,842 shares of ARTIVION common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged Rule 10b5-1 plan, which typically mitigates concerns that the sale is based on new, non-public information. Therefore, it is largely neutral in sentiment, though any reduction in insider ownership is noted.

Negatives

• The Chief Commercial Officer reduced his direct beneficial ownership in the company by 5,000 shares.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive landscape beyond the individual's trading activity.

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, though the pre-arranged nature of the sale under Rule 10b5-1(c) suggests it was not driven by new, adverse company developments.

Key Dates

Recommendation

While insider selling can sometimes be a negative signal, this transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily based on new, non-public information. A single Form 4 filing, especially one under a 10b5-1 plan, is generally not sufficient to alter a fundamental investment thesis. Investors should monitor for further insider activity and broader company performance rather than making a significant decision based solely on this routine disclosure.

Keywords

ARTIVION, AORT, Insider Trading, Stock Sale, Form 4, John E. Davis, Chief Commercial Officer, 10b5-1 Plan